Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2012

Summary of Significant Accounting Policies

Summary of the activity of each major category of revenue allowance

For the six months ended December 31, 2012

(In thousands)
Reserve Category	Chargebacks			Rebates			Returns			Other			Total
Reserve Balance as of July 1, 2012	$	7,063		$	4,436		$	5,540		$	—		$	17,039
Actual credits issued related to sales recorded in prior fiscal years	(6,584		)	(4,000		)	(1,644		)	(61		)	(12,289		)
Reserves or (reversals) charged during Fiscal 2013 related to sales in prior fiscal years	(461		)	131			—			61			(269		)
Reserves charged to net sales during Fiscal 2013 related to sales recorded in Fiscal 2013	37,235			11,951			2,456			1,250			52,892
Actual credits issued related to sales recorded in Fiscal 2013	(29,176		)	(7,986		)	—			(1,250		)	(38,412		)
Reserve Balance as of December 31, 2012	$	8,077		$	4,532		$	6,352		$	—		$	18,961

For the six months ended December 31, 2011

(In thousands)
Reserve Category	Chargebacks			Rebates			Returns			Other			Total
Reserve Balance as of July 1, 2011	$	5,497		$	2,925		$	5,142		$	—		$	13,564
Actual credits issued related to sales recorded in prior fiscal years	(5,213		)	(2,985		)	(2,469		)	(133		)	(10,800		)
Reserves or (reversals) charged during Fiscal 2012 related to sales in prior fiscal years	(62		)	255			—			133			326
Reserves charged to net sales during Fiscal 2012 related to sales recorded in Fiscal 2012	34,292			10,211			2,444			356			47,303
Actual credits issued related to sales recorded in Fiscal 2012	(27,488		)	(5,663		)	—			(356		)	(33,507		)
Reserve Balance as of December 31, 2011	$	7,026		$	4,743		$	5,117		$	—		$	16,886

Summary of the activity of reserves for each of the major category of revenue allowance

	December 31, 2012				June 30, 2012
(In thousands)	$		%		$		%
Chargeback reserve	$	8,077	43	%	$	7,063	41	%
Rebate reserve	4,532		24	%	4,436		26	%
Return reserve	6,352		33	%	5,540		33	%
Other reserve	—		—	%	—		—	%
	$	18,961	100	%	$	17,039	100	%

Summary of net product sales by medical indication

(In thousands)	For the Three Months Ended December 31,				For the Six Months Ended December 31,
Medical Indication	2012		2011		2012		2011
Migraine Headache	$	1,447	$	1,547	$	2,696	$	3,159
Glaucoma	1,608		1,068		2,981		2,100
Gallstone Prevention	1,708		1,567		3,286		2,867
Cardiovascular	7,269		2,952		14,369		5,462
Thyroid Deficiency	14,474		11,211		28,111		24,246
Antibiotic	1,082		1,457		2,771		3,136
Pain Management	4,240		5,257		9,772		10,566
Obesity	1,104		1,044		2,414		1,591
Other	3,632		1,631		5,458		3,485
Total	$	36,564	$	27,734	$	71,858	$	56,612

Summary of certain of the Company's products which accounted for greater than 10% of net sales

	For the Three Months Ended December 31,				For the Six Months Ended December 31,
	2012		2011		2012		2011
Product 1	40	%	40	%	39	%	43	%
Product 2	12	%	1	%	11	%	1	%
Product 3	10	%	8	%	9	%	10	%

Summary of certain of the Company's customers which accounted for greater than 10% of net sales

	For the Three Months Ended December 31,				For the Six Months Ended December 31,
	2012		2011		2012		2011
Customer A	16	%	17	%	17	%	19	%
Customer B	13	%	11	%	12	%	11	%
Customer C	10	%	19	%	10	%	15	%